NCT06030076

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Name: Clinical Trial NCT06030076
Creator: Almirall, S.A.
Keywords: Plaque Psoriasis, Tildrakizumab, drug, clinical trial

A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and Switzerland

Almirall, S.A.·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Plaque Psoriasis
Drug/Device/Intervention: Tildrakizumab
Study type: Observational
Intervention type: drug

Sponsor & location

Primary sponsor: Almirall, S.A.

Timeline & enrollment

Phase: N/A
Start date: Sep 15, 2023
End date: Jan 01, 2025
Enrollment: 50 participants

Primary outcome

Treatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score,World Health Organisation Well-Being Index (WHO-5) Score

Summary

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.

ICD-10 classifications

PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06030076
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06030076 through Pure Global AI's free database. This phase not specified trial is sponsored by Almirall, S.A. and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.